# BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

> **NCT03627390** · PHASE2 · COMPLETED · sponsor: **Meabco A/S** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer
- Unresectable Pancreatic Cancer

## Interventions

- **DRUG:** BP-C1
- **DRUG:** BP-C2

## Key facts

- **NCT ID:** NCT03627390
- **Lead sponsor:** Meabco A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-19
- **Primary completion:** 2016-03-04
- **Final completion:** 2016-03-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-11-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03627390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03627390, "BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03627390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*